Cerus Corp.
- CERS · Nasdaq
- Surgical & Medical Instruments & Apparatus
- Concord, CA
- 275 employees
- CIK 0001020214
Updated from SEC filings through
Top things to know
Executives
- Vivek Jayaraman Cerus’s president and chief executive officer 8-K, 2026-11-02
- Vivek K. Jayaraman Chief Executive Officer 4, 2026-07-20
- William Mariner Greenman President and CEO 4, 2026-07-02
- Kevin Dennis Green Chief Financial Officer 4, 2026-07-02
- Kevin D. Green Vice President, Finance and Chief Financial Officer 10-K, 2026-03-02
- Chrystal Jensen Chief Legal Officer 4, 2026-08-17
What leadership is saying
“Our solid performance in Q3 builds upon a strong first half of 2026 and increases our confidence as we approach year-end”
Earnings press release (8-K Ex. 99.1), filed November 2, 2026
Cerus Corp is a U.S. public company in surgical & medical instruments & apparatus (SIC 3841), headquartered in Concord, CA. It trades as CERS on Nasdaq. Revenue was $234M in the fiscal year ending December 31, 2025, +16.1% from the year before. It reported about 275 employees. Vivek Jayaraman is Cerus’s president and chief executive officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $234M 10-K, 2026-03-02 | $201M 10-K, 2026-03-02 | $187M 10-K, 2026-03-02 | $188M 10-K, 2025-02-26 | $160M 10-K, 2024-03-05 |
| Operating income | -$8.7M 10-K, 2026-03-02 | -$14.2M 10-K, 2026-03-02 | -$30.1M 10-K, 2026-03-02 | -$34.1M 10-K, 2025-02-26 | -$48.9M 10-K, 2024-03-05 |
| SG&A | $80.9M 10-K, 2026-03-02 | $75.9M 10-K, 2026-03-02 | $75.5M 10-K, 2026-03-02 | $83.3M 10-K, 2025-02-26 | $81.3M 10-K, 2024-03-05 |
| Net income | -$15.6M 10-K, 2026-03-02 | -$20.9M 10-K, 2026-03-02 | -$37.5M 10-K, 2026-03-02 | -$42.8M 10-K, 2025-02-26 | -$54.4M 10-K, 2024-03-05 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Vivek Jayaraman | Cerus’s president and chief executive officer | 8-K, 2026-11-02 |
| Vivek K. Jayaraman President and Chief Executive Officer at Cerus | Chief Executive Officer | 4, 2026-07-20 |
| William Mariner Greenman | President and CEO | 4, 2026-07-02 |
| Kevin Dennis Green | Chief Financial Officer | 4, 2026-07-02 |
| Kevin D. Green | Vice President, Finance and Chief Financial Officer | 10-K, 2026-03-02 |
| Chrystal Jensen | Chief Legal Officer | 4, 2026-08-17 |
 Richard Benjamin | Named in proxy bio: Chief Medical Officer | DEF 14A, 2026-04-22 |
| Richard J. Benjamin | Chief Medical Officer | 4, 2026-03-16 |
| Ann Lucena | Director | 10-K, 2026-03-02 |
| Dean A. Gregory | Director | 10-K, 2026-03-02 |
| Eric H. Bjerkholt | Director | 10-K, 2026-03-02 |
| Frank Witney, Ph.D. | Director | 10-K, 2026-03-02 |
| Jami Nachtsheim | Director | 10-K, 2026-03-02 |
| Timothy L. Moore | Director | 10-K, 2026-03-02 |
What Cerus Corp does
We are a biomedical products company focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on our proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 202.0 million (as of October 16, 2026) | 10-Q, November 2, 2026 |
|---|---|---|
| Public float | $230M (as of June 30, 2025) | 10-K, March 2, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 2, 2026 |
| Latest proxy statement | Meeting April 22, 2026 (filed April 22, 2026) | DEF 14A, April 22, 2026 |
| Auditor | Ernst & Young LLP (San Francisco, California) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| August 17, 2026 | Chrystal Jensen Chief Legal Officer | Sale | 30,000 | $89K | Form 4, August 17, 2026 |
| July 16, 2026 | Vivek K. Jayaraman Chief Executive Officer | Sale | 16,666 | $53K | Form 4, July 20, 2026 |
| June 30, 2026 | Vivek K. Jayaraman Chief Operating Officer | Sale | 42,359 | $125K | Form 4, July 2, 2026 |
| June 30, 2026 | Chrystal Jensen Chief Legal Officer | Sale | 24,329 | $72K | Form 4, July 2, 2026 |
| June 30, 2026 | Kevin Dennis Green Chief Financial Officer | Sale | 33,676 | $99K | Form 4, July 2, 2026 |
| June 30, 2026 | William Mariner Greenman President and CEO | Sale | 101,919 | $300K | Form 4, July 2, 2026 |
| June 9, 2026 | Eric Bjerkholt Director | Sale | 20,454 | $53K | Form 4, June 11, 2026 |
| May 29, 2026 | Vivek K. Jayaraman Chief Operating Officer | Sale | 16,667 | $50K | Form 4, June 2, 2026 |
Recent 8-K events
- 8-K filed 2026-11-02
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-30
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-10
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-06-08
- Item 1.01 Entry into a material definitive agreement
- Item 1.02 Termination of a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- 8-K filed 2026-06-03
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-04-30
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-21
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-03-16
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-03-02
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-01-23
- Item 5.02 Departure or appointment of directors or officers; compensation
Frequently asked questions about Cerus Corp
- What does Cerus Corp do?
- In its own words, from Item 1 of its 10-K: "We are a biomedical products company focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on our proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion."
- What is Cerus Corp's revenue?
- $234M for the fiscal year ending December 31, 2025, from its 10-K filed March 2, 2026.
- Is Cerus Corp profitable?
- Cerus Corp reported net income of -$15.6M for the fiscal year ending December 31, 2025.
- How many employees does Cerus Corp have?
- About 275 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Cerus Corp?
- Vivek Jayaraman, Cerus’s president and chief executive officer, as named in a 8-K filed November 2, 2026.
- Who is the CFO of Cerus Corp?
- Kevin Dennis Green, Chief Financial Officer, as named in a 4 filed July 2, 2026.
- Where is Cerus Corp headquartered?
- Concord, CA.
- What is Cerus Corp's stock ticker?
- CERS on Nasdaq.
- What industry is Cerus Corp in?
- Surgical & Medical Instruments & Apparatus, SIC code 3841.
- What is Cerus Corp's website?
- cerus.com.
- When does Cerus Corp report earnings next?
- January 8, 2027. Source: estimate_8k_pattern.
- Is Cerus Corp a public company?
- Yes. Cerus Corp files with the SEC under CIK 0001020214 and trades as CERS.
- Who audits Cerus Corp?
- Ernst & Young LLP, San Francisco, California, as named in its latest annual report (10-K).
- How many shares of Cerus Corp are outstanding?
- 202.0 million shares as of October 16, 2026, from its 10-Q filed November 2, 2026.
- What is Cerus Corp's public float?
- $230M as of June 30, 2025, as reported on the cover of its 10-K filed March 2, 2026.
- How many business segments does Cerus Corp report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 2, 2026.
- When is Cerus Corp's annual shareholder meeting?
- April 22, 2026, per its proxy statement (DEF 14A) filed April 22, 2026.
- Have Cerus Corp insiders traded stock recently?
- Since March 12, 2025, officers and directors reported 20 open-market sales worth about $3.3M and 1 purchase worth about $31K on Forms 4 and 5. The most recent: Chrystal Jensen (Chief Legal Officer) sold 30,000 shares on August 17, 2026.